Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fuji
Chubb
Deloitte
Farmers Insurance
Julphar
Cerilliant
Healthtrust
Citi
Baxter
Cantor Fitzgerald

Generated: October 17, 2017

DrugPatentWatch Database Preview

Daiichi Sankyo Inc Company Profile

« Back to Dashboard

What is the competitive landscape for DAIICHI SANKYO INC, and when can generic versions of DAIICHI SANKYO INC drugs launch?

DAIICHI SANKYO INC has four approved drugs.

There are three US patents protecting DAIICHI SANKYO INC drugs.

There are one hundred and two patent family members on DAIICHI SANKYO INC drugs in twenty-eight countries and seven supplementary protection certificates in five countries.

Summary for Applicant: Daiichi Sankyo Inc

International Patents:102
US Patents:3
Tradenames:4
Ingredients:4
NDAs:4
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Daiichi Sankyo Inc
MORPHABOND ER
morphine sulfate
TABLET, EXTENDED RELEASE;ORAL206544-002Oct 2, 2015RXYesNo► Subscribe► Subscribe► Subscribe
Daiichi Sankyo Inc
SAVAYSA
edoxaban tosylate
TABLET;ORAL206316-001Jan 8, 2015RXYesNo► Subscribe► Subscribe► Subscribe
Daiichi Sankyo Inc
ROXYBOND
oxycodone hydrochloride
TABLET;ORAL209777-002Apr 20, 2017RXNoNo► Subscribe► SubscribeY ► Subscribe
Daiichi Sankyo Inc
SAVAYSA
edoxaban tosylate
TABLET;ORAL206316-001Jan 8, 2015RXYesNo► Subscribe► SubscribeY ► Subscribe
Daiichi Sankyo Inc
SAVAYSA
edoxaban tosylate
TABLET;ORAL206316-003Jan 8, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Daiichi Sankyo Inc
SAVAYSA
edoxaban tosylate
TABLET;ORAL206316-002Jan 8, 2015RXYesNo► Subscribe► Subscribe► Subscribe
Daiichi Sankyo Inc
SAVAYSA
edoxaban tosylate
TABLET;ORAL206316-003Jan 8, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Daiichi Sankyo Inc
MORPHABOND ER
morphine sulfate
TABLET, EXTENDED RELEASE;ORAL206544-003Oct 2, 2015RXYesNo► Subscribe► SubscribeY ► Subscribe
Daiichi Sankyo Inc
SAVAYSA
edoxaban tosylate
TABLET;ORAL206316-001Jan 8, 2015RXYesNo► Subscribe► SubscribeY ► Subscribe
Daiichi Sankyo Inc
MORPHABOND ER
morphine sulfate
TABLET, EXTENDED RELEASE;ORAL206544-001Oct 2, 2015RXYesNo► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Daiichi Sankyo Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Daiichi Sankyo Inc
EVOXAC
cevimeline hydrochloride
CAPSULE;ORAL020989-002Jan 11, 2000► Subscribe► Subscribe
Daiichi Sankyo Inc
EVOXAC
cevimeline hydrochloride
CAPSULE;ORAL020989-002Jan 11, 2000► Subscribe► Subscribe
Daiichi Sankyo Inc
EVOXAC
cevimeline hydrochloride
CAPSULE;ORAL020989-002Jan 11, 2000► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for DAIICHI SANKYO INC drugs

Drugname Dosage Strength Tradename Submissiondate
cevimeline hydrochloride
Capsules30 mg
EVOXAC
2/27/2009

Non-Orange Book Patents for Daiichi Sankyo Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,342,014Diamine derivatives► Subscribe
9,707,296Pharmaceutical composition► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Daiichi Sankyo Inc Drugs

Country Document Number Estimated Expiration
Canada2680039► Subscribe
Russian Federation2004101279► Subscribe
China1826333► Subscribe
Austria556066► Subscribe
TaiwanI298066► Subscribe
South Korea20040029322► Subscribe
South Korea100908966► Subscribe
Japan2016138126► Subscribe
South Africa200906182► Subscribe
Australia2009282376► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Daiichi Sankyo Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
835Luxembourg► SubscribePRODUCT NAME: EDOXABAN, UN DE SES SELS, UN DE SES SOLVATES OU UN N-OXYDE DE CELUI-CI, EN PARTICULIER UN TOSYLATE D EDOXABAN. FIRST REGISTRATION: 20150619
2015 00052Denmark► SubscribePRODUCT NAME: EDOXABAN, HERUNDER EDOXABAN TOSILATE; REG. NO/DATE: EU/1/15/993/001-028 20150623
2015000077Germany► SubscribePRODUCT NAME: EDOXABAN, DESSEN SALZ, DESSEN SOLVAT, ODER DESSEN N-OXID, INSBESONDERE EDOXABANTOSILAT; REGISTRATION NO/DATE: EU/1/15/993/001-028 20150619
2015 00052Denmark► SubscribePRODUCT NAME: EDOXABAN, OR A SALT THEREOF, A SOLVATE THEREOF, OR AN N-OXIDE THEREOF, IN PARTICULAR EDOXABAN TOSYLATE; REG. NO/DATE: EU/1/15/993/001-028 20150623
292Luxembourg► SubscribePRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE
0760Netherlands► SubscribePRODUCT NAME: EDOBAXAN, EEN ZOUT DAARVAN, EEN SOLVAAT DAARVAAN OF EEN N-OXIDE DAARVAN, IN HET BIJZONDER EDOBAXAN TOSYLAAT; REGISTRATION NO/DATE: EU/1/15/993/001-028 20150619
C0068France► SubscribePRODUCT NAME: EDOXABAN,UN SEL,SOLVATE OU N-OXYDE DE CELUI-CI,EN PARTICULIER L'EDOXABAN TOSYLATE; REGISTRATION NO/DATE: EU/1/15/993 20150619
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Daiichi Sankyo
Colorcon
Farmers Insurance
McKinsey
Chubb
Federal Trade Commission
Accenture
Baxter
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot